<DOC>
	<DOCNO>NCT00030381</DOCNO>
	<brief_summary>Iododoxorubicin may dissolve protein deposit effective treatment primary systemic amyloidosis . Phase I trial determine effectiveness iododoxorubicin treat patient primary systemic amyloidosis</brief_summary>
	<brief_title>Iododoxorubicin Treating Patients With Primary Systemic Amyloidosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose iododoxorubicin patient primary systemic amyloidosis . SECONDARY OBJECTIVES : I . Determine safety , especially cardiac safety , drug patient . II . Determine survival rate patient treat drug . III . Determine , preliminarily , clinical efficacy drug patient . IV . Determine pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients receive iododoxorubicin IV 15 minute day 1 , 8 , 15 , 22 . Treatment repeat every 12 week total 4 course cumulative dose 400 mg/m^2 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos iododoxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 3 month .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Esorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Histochemically confirm amyloidosis polarize microscopy greenbirefringent material Congo redstained tissue specimen At least one following : Demonstrable Mprotein serum urine Clonal population plasma cell bone marrow Immunohistochemical stain antilight chain antiserum amyloid fibrils Symptomatic organ involvement , include liver involvement , mild cardiac involvement , renal involvement , grade 1 2 peripheral neuropathy , soft tissue involvement ( include tongue ) No purpura carpal tunnel syndrome sole manifestation disease No clinically overt multiple myeloma define monoclonal bone marrow platelet concentration great 20 % least one following : Bone lesion Anemia Hypercalcemia Performance status ECOG 03 ( 3 allow related muscular infiltration amyloid peripheral neuropathy ) Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Total bilirubin great 2.0 mg/dL Direct bilirubin great 1.0 mg/dL Alkaline phosphatase great 4 time upper limit normal ( ULN ) AST ALT great 3 time ULN Creatinine clearance least 40 mL/min Ejection fraction least 50 % echocardiogram No New York Heart Association class III IV heart disease No enzymedocumented myocardial infarction within past 3 year No chronic atrial fibrillation No grade 2 3 atrioventricular block ( Mobitz type I allow ) No sustain ( great 30 second ) ventricular tachycardia , 1 episode nonsustained ventricular tachycardia ( 3 consecutive ventricular beat ) , frequent ( 20 24 hour ) ventricular pair 24hour ambulatory electrocardiographic monitoring No intraventricular septum great 16 mm echocardiogram Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled infection No active malignancy except nonmelanoma skin cancer cervical cancer No psychiatric illness social situation would preclude study No severe diarrhea ( great grade 3 ) controllable medication require total parenteral nutrition More 4 week since prior interferon alfa No concurrent immunotherapy More 4 week since prior melphalan alkylating agent No prior anthracycline exposure great 120 mg/m^2 Recovered prior chemotherapy No concurrent chemotherapy More 4 week since prior highdose dexamethasone No concurrent radiotherapy No concurrent investigational ancillary therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>